Daraxonrasib Shows Nearly 50% Survival Benefit in Advanced Pancreatic Cancer

Pancreatic cancer patients with limited treatment options now have access to a potentially life-extending therapy through early access programs.

For decades, a diagnosis of metastatic pancreatic cancer with RAS mutations left patients with little more than diminishing options and narrowing time. In May 2026, a drug called Daraxonrasib — designed to target the long-considered-undruggable RAS mutation — has begun reaching patients through an FDA-authorized early access program, backed by trial data showing median survival nearly doubled compared to standard chemotherapy. It is the kind of development that does not merely extend a statistic, but reopens a door that medicine had quietly closed for an entire population of patients.

Daraxonrasib Shows Nearly 50% Survival Benefit in Advanced Pancreatic Cancer

Cobertura Relacionada

Receba o Register no seu e-mail